Autres langues Catalyst Pharmaceuticals, Inc.

Actions

CPRX

US14888U1016

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
14,89 ^USD	+1,43%		-1,59%	-11,42%

25/04	Santhera dans les chiffres noirs en 2023	AW
10/04	Un initié de Catalyst Pharmaceuticals a vendu des actions pour une valeur de 392 000 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024	22/04
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	10/04
Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04
Certain Restricted Stock Units of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04
Certain Common Stock of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	28/03
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day	28/03
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium	27/03
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	14/03
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States	14/03
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy	13/03
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13/03
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13/03
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	13/03
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals	07/03
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05/03
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05/03
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	29/02
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Catalyst Pharmaceuticals, Inc. : Scénario optimiste

Le 06 mars 2023 à 16:12